K. N. Chi Et Al. , "Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021
Chi, K. N. Et Al. 2021. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6 .
Chi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., de Santana Gomes, A. J. P., Given, R., ... Soto, A. J.(2021). Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.
Chi, Kim Et Al. "Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).," JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021
Chi, Kim N. Et Al. "Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6, 2021
Chi, K. N. Et Al. (2021) . "Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).." JOURNAL OF CLINICAL ONCOLOGY , vol.39, no.6.
@article{article, author={Kim N. Chi Et Al. }, title={Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2021}